TickerFacts.

Kalaris Therapeutics, Inc. (KLRS): Capital Expenditures

Annual figures by period end, from SEC filings.

$200.0K
Year ended 2025-12-31
-3.2%
5-year compound annual growth
$339.0K2019-12-31: $339.0K2020-12-31: $235.0K2021-12-31: $26.0K2025-12-31: $200.0K$200.0K
2019-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$200.0Kn/a2026-03-17, From 2025-01-01
No annual figure between 2021-12-31 and 2025-12-31.
2021-12-31$26.0K-88.9%2023-02-15, From 2021-01-01
2020-12-31$235.0K-30.7%2022-02-10, From 2020-01-01
2019-12-31$339.0Kn/a2021-02-12, From 2019-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Kalaris Therapeutics, Inc. (KLRS)2025-12-31$200.0Kn/a
Acumen Pharmaceuticals, Inc. (ABOS)2025-12-31$88.0K+450.0%
Candel Therapeutics, Inc. (CADL)2025-12-31$587.0Kn/m
Humacyte, Inc. (HUMA)2025-12-31$884.0K-43.8%
Zura Bio Ltd (ZURA)2025-12-31$113.0K+50.7%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$99.0Kn/a
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31$2.59M+303.0%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$522.0K-7.6%
Palisade Bio, Inc. (PALI)2024-12-31$0-100.0%

Compare KLRS, ABOS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗